サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1387488

がんモノクローナル抗体市場レポート：2030年までの動向、予測、競合分析

Cancer Monoclonal Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

がんモノクローナル抗体市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年11月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

がんモノクローナル抗体の動向と予測

世界のがんモノクローナル抗体市場は、2024年から2030年までのCAGRが12.4%で、2030年までに推定1,537億米ドルに達すると予想されます。この市場の主な促進要因は、研究開発活動への投資の増加、個別化医療への志向の高まり、世界のがん罹患率の増加です。世界のがんモノクローナル抗体市場の将来は、病院や研究機関市場の機会によって有望視されています。

がんモノクローナル抗体市場洞察

Lucintelの予測では、マウスモノクローナル抗体は価格が手ごろで入手しやすく、生産にかかる時間が短いため、ヒト化抗体は予測期間中に最も高い成長を遂げる見込みです。

この市場では、がんの有病率の増加と入院患者数の増加により、病院が最大のセグメントであり続けるでしょう。

北米は、先進治療に対する意識の高まり、がん有病率の上昇、同地域における主要市場参入企業の存在により、予測期間中も最大地域であり続けると思われます。

本レポートでは、以下の11の主要な質問について回答する：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.今後成長が加速するセグメントとその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のがんモノクローナル抗体市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018～2030年の市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のがんモノクローナル抗体市場動向（2018～2023）と予測（2024～2030）
  • タイプ別の世界のがんモノクローナル抗体市場
    • ヒト化
    • ヒト
    • キメラ
    • ネズミ
  • 用途別の世界のがんモノクローナル抗体市場
    • 血液がん
    • 乳がん
    • 肺がん
    • 黒色腫
    • 結腸直腸がん
    • 肝臓がん
    • その他
  • 最終用途別の世界のがんモノクローナル抗体市場
    • 病院
    • 研究機関
    • その他

第4章 2018～2030年の地域別の市場動向と予測分析

  • 地域別の世界のがんモノクローナル抗体市場
  • 北米のがんモノクローナル抗体市場
  • 欧州のがんモノクローナル抗体市場
  • アジア太平洋のがんモノクローナル抗体市場
  • その他地域のがんモノクローナル抗体市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • タイプ別の世界のがんモノクローナル抗体市場の成長機会
    • 用途別の世界のがんモノクローナル抗体市場の成長機会
    • 最終用途別の世界のがんモノクローナル抗体市場の成長機会
    • 地域別の世界のがんモノクローナル抗体市場の成長機会
  • 世界のがんモノクローナル抗体市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のがんモノクローナル抗体市場の能力拡大
    • 世界のがんモノクローナル抗体市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie
目次

Cancer Monoclonal Antibodies Trends and Forecast

The future of the global cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets. The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030 with a CAGR of 12.4% from 2024 to 2030. The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

A more than 150-page report is developed to help in your business decisions.

Cancer Monoclonal Antibodies by Segment

The study includes a forecast for the global cancer monoclonal antibodies by type, application, end use, and region.

Cancer Monoclonal Antibodies Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Humanized
  • Human
  • Chimeric
  • Murine

Cancer Monoclonal Antibodies Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Others

Cancer Monoclonal Antibodies Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Research Institutes
  • Others

Cancer Monoclonal Antibodies Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Monoclonal Antibodies Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer monoclonal antibodies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer monoclonal antibodies companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Cancer Monoclonal Antibodies Market Insights

Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Within this market, hospitals will remain the largest segment due increasing prevalence of cancer along with growing number of patient hospitalizations.

North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Features of the Global Cancer Monoclonal Antibodies Market

Market Size Estimates: Cancer monoclonal antibodies market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer monoclonal antibodies market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Cancer monoclonal antibodies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the cancer monoclonal antibodies market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer monoclonal antibodies market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer monoclonal antibodies market size?

Answer: The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030.

Q2. What is the growth forecast for cancer monoclonal antibodies market?

Answer: The global cancer monoclonal antibodies market is expected to grow with a CAGR of 12.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer monoclonal antibodies market?

Answer: The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

Q4. What are the major segments for cancer monoclonal antibodies market?

Answer: The future of the cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets.

Q5. Who are the key cancer monoclonal antibodies market companies?

Answer: Some of the key cancer monoclonal antibodies companies are as follows:

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Q6. Which cancer monoclonal antibodies market segment will be the largest in future?

Answer: Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Q7. In cancer monoclonal antibodies market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer monoclonal antibodies market by type (humanized, human, chimeric, and murine), application (blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Monoclonal Antibodies Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Monoclonal Antibodies Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Monoclonal Antibodies Market by Type
    • 3.3.1: Humanized
    • 3.3.2: Human
    • 3.3.3: Chimeric
    • 3.3.4: Murine
  • 3.4: Global Cancer Monoclonal Antibodies Market by Application
    • 3.4.1: Blood Cancer
    • 3.4.2: Breast Cancer
    • 3.4.3: Lung Cancer
    • 3.4.4: Melanoma
    • 3.4.5: Colorectal Cancer
    • 3.4.6: Liver Cancer
    • 3.4.7: Others
  • 3.5: Global Cancer Monoclonal Antibodies Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Research Institutes
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Monoclonal Antibodies Market by Region
  • 4.2: North American Cancer Monoclonal Antibodies Market
    • 4.2.2: North American Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.3: European Cancer Monoclonal Antibodies Market
    • 4.3.1: European Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.3.2: European Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.4: APAC Cancer Monoclonal Antibodies Market
    • 4.4.1: APAC Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.4.2: APAC Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.5: ROW Cancer Monoclonal Antibodies Market
    • 4.5.1: ROW Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.5.2: ROW Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Type
    • 6.1.2: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Application
    • 6.1.3: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Region
  • 6.2: Emerging Trends in the Global Cancer Monoclonal Antibodies Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Monoclonal Antibodies Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Monoclonal Antibodies Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Bristol Myers Squibb
  • 7.3: Merck
  • 7.4: GlaxoSmithKline
  • 7.5: Johnson & Johnson
  • 7.6: Amgen
  • 7.7: Novartis
  • 7.8: AstraZeneca
  • 7.9: Eli Lilly
  • 7.10: AbbVie